All In Biotech

Drug Trial Radar · NCT03548935

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Nov 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,961 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,961

Actual

Start

Jun 4, 2018

Primary completion

Mar 30, 2020

Study completion Mar 5, 2021

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what you can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment participants get, is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study has two phases: A main phase and an extension phase.The main phase will last for about 1.5 years. Participants will have 15 clinic visits and 10 phone calls with the study doctor. Extension phase: Approximately 300 participants will continue in the extension phase in the following countries only: Canada, Germany, the UK and selected sites in the US and Japan. These participants will be in the study for about 2.5 years.They will not receive treatment, but will attend another 5 follow-up visits with the study doctor.

Conditions

  • Metabolism and Nutrition Disorder
  • Overweight or Obesity

Interventions

  • SemaglutideDrug

    Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.

  • Placebo (semaglutide)Drug

    Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Body Weight (%)Time frame: Baseline (week 0) to week 68
  2. Participants Who Achieve 5 or More Percent Body Weight Reduction (Yes/no)Time frame: After week 68

Locations

128 sites in 17 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Anniston, Alabama

  • Novo Nordisk Investigational Site

    Anaheim, California

  • Novo Nordisk Investigational Site

    Lomita, California

  • Novo Nordisk Investigational Site

    Spring Valley, California

  • Novo Nordisk Investigational Site

    Aurora, Colorado

  • Novo Nordisk Investigational Site

    Waterbury, Connecticut

  • Novo Nordisk Investigational Site

    Chiefland, Florida

  • Novo Nordisk Investigational Site

    Crystal River, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Ocala, Florida

  • Novo Nordisk Investigational Site

    Panama City, Florida

  • Novo Nordisk Investigational Site

    Plantation, Florida

  • Novo Nordisk Investigational Site

    Ponte Vedra, Florida

  • Novo Nordisk Investigational Site

    Roswell, Georgia

  • Novo Nordisk Investigational Site

    Chicago, Illinois

  • Novo Nordisk Investigational Site

    Chicago, Illinois

  • Novo Nordisk Investigational Site

    Indianapolis, Indiana

  • Novo Nordisk Investigational Site

    Topeka, Kansas

  • Novo Nordisk Investigational Site

    Louisville, Kentucky

  • Novo Nordisk Investigational Site

    Buckley, Michigan

  • Novo Nordisk Investigational Site

    City of Saint Peters, Missouri

  • Novo Nordisk Investigational Site

    Butte, Montana

  • Novo Nordisk Investigational Site

    Omaha, Nebraska

  • Novo Nordisk Investigational Site

    Rochester, New York

  • Novo Nordisk Investigational Site

    Salisbury, North Carolina

  • Novo Nordisk Investigational Site

    Wilmington, North Carolina

  • Novo Nordisk Investigational Site

    West Reading, Pennsylvania

  • Novo Nordisk Investigational Site

    Charleston, South Carolina

  • Novo Nordisk Investigational Site

    Simpsonville, South Carolina

  • Novo Nordisk Investigational Site

    Nashville, Tennessee

  • Novo Nordisk Investigational Site

    Austin, Texas

  • Novo Nordisk Investigational Site

    Dallas, Texas

  • Novo Nordisk Investigational Site

    Dallas, Texas

  • Novo Nordisk Investigational Site

    Dallas, Texas

  • Novo Nordisk Investigational Site

    Round Rock, Texas

  • Novo Nordisk Investigational Site

    Bountiful, Utah

  • Novo Nordisk Investigational Site

    Richmond, Virginia

  • Novo Nordisk Investigational Site

    Renton, Washington

  • Novo Nordisk Investigational Site

    CABA, Argentina

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.